NCT07066709 Painful Post-Operative Hip Study
| NCT ID | NCT07066709 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Wisconsin, Madison |
| Condition | Unilateral Hip Arthroscopy |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2026-01-21 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 15 participants in total. It began in 2026-01-21 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if the hips of people who undergo revision hip arthroscopy look different from the hips of people whose hip pain is resolved with the first hip arthroscopy and of people who choose the steroid injection for pain management. Participants will complete one PET/MRI scan.
Eligibility Criteria
Inclusion Criteria: * Age 18-45 * History of unilateral hip arthroscopy * Does not have evidence of fracture, infection, or malignancy at 6 months post-hip arthroscopy * Does not have evidence of depression or other major mental health conditions before the index hip arthroscopy * Does not have persistent pain that requires opioid use, or does not have a history of opioid abuse * Does not have any comorbidity results in systemic disease limiting function (ASA physical status classification \>3) * Not currently pregnant * Presents with persistent pain (≥4/10 on NRS) for at least 6 months post-hip arthroscopy * Undergo a revision hip arthroscopy with no surgical history on the contralateral limb Exclusion Criteria: * No unilateral hip arthroscopy * Evidence of fracture, infection, or malignancy at 6 months post-hip arthroscopy * Evidence of depression or other major mental health conditions before the index hip arthroscopy * Has persistent pain that requires opioid use, or has a history of opioid abuse * Has any comorbidity results in systemic disease limiting function (ASA physical status classification \<3) * Currently pregnant
Contact & Investigator
Andrea Spiker, MD
PRINCIPAL INVESTIGATOR
University of Wisconsin, Madison
Frequently Asked Questions
Who can join the NCT07066709 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Unilateral Hip Arthroscopy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07066709 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07066709 currently recruiting?
Yes, NCT07066709 is actively recruiting participants. Contact the research team at armstrong@ortho.wisc.edu for enrollment information.
Where is the NCT07066709 trial being conducted?
This trial is being conducted at Madison, United States.
Who is sponsoring the NCT07066709 clinical trial?
NCT07066709 is sponsored by University of Wisconsin, Madison. The principal investigator is Andrea Spiker, MD at University of Wisconsin, Madison. The trial plans to enroll 15 participants.